


CLAIMS

1. A method for the prophylaxis or treatment of infection by a microorganism in a biological environment from where the microorganism acquires iron, heme or porphyrin said method comprising administering to said environment an effective amount of an agent for a time and under conditions sufficient to antagonize the interaction between a molecule derived from said microorganism and having an HA2 domain and an HA2-binding motif on a porphyrin containing molecule present in said biological environment.
2. A method according to Claim 1 wherein the microorganism is *Porphyromonas gingivalis* or a related microorganism.
3. A method according to Claim 3 wherein the biological environment is a mammal or reptile or insect or bird or species of fish.
4. A method according to Claim 3 wherein the mammal is a primate, human, livestock animal or a companion animal.
5. A method according to any one of Claims 1 to 4 when used for the treatment of a disease condition in the oral cavity, nasopharynx, oropharynx, vagina or urethra or other vascular or mucosal regions or cavities or in the hooves of livestock animals.
6. A method according to any one of Claims 1 to 5 wherein the HA2-containing molecule is a gingipain, an hagA gene product or a TonB-dependent protein such as but not limited to Tla protein or a homologue thereof.
7. A method according to Claim 1 or 6 wherein the porphyrin moiety is heme.
8. A method according to Claim 7 wherein the HA2-binding motif comprises a region comprising or within substructure (Ic) of structure (I):

- 57 -



wherein R_1 and R_6 are the same or different and each is an alkyl such as a methyl, ethyl or propyl group, or hydrogen, hydroxyl, carboxyl, aldehyde, acetaldehyde or keto group, M is a metal ion in various oxidation states such as but not limited to Fe , Fe^{++} and Fe^{+++} and is optionally present such that n is 0 or 1 or a structurally or functional homologue thereof.

9. A method for the prophylaxis or treatment of infection by a microorganism in a mammal, said microorganism substantially requiring exogenous iron, heme or porphyrin for growth or maintenance wherein said method comprises administering to said mammal an effective amount of an agent for a time and under conditions sufficient to antagonize the interaction between a molecule derived from said microorganism and having an HA2 domain and an HA2-binding moiety on a porphyrin-containing molecule such as but not limited to hemoglobin or a precursor form thereof or part thereof such as heme and wherein said HA2 domain comprises:

- (i) an amino acid sequence substantially encoded by the nucleotide sequence set forth in <400>5 or a nucleotide sequence having at least about 40% similarity thereto or capable of hybridizing thereto under low stringency conditions; and/or

- 58 -

- (ii) an amino acid sequence substantially as set forth in <400>6 or an amino acid sequence having at least about 40% similarity thereto or at least about 20% identity after optimum alignment with same sequence.;

wherein said amino acid sequence is capable of interacting with an HA2-binding moiety on a porphyrin-containing molecule such as but not limited to hemoglobin or a precursor form thereof or part thereof such as heme.

10. A method for prophylaxis or treatment of periodontal, pulmonary, vaginal, urethral or hoof disease resulting from infection by *P. gingivalis* or related microorganism in a mammal said method comprising administering to said mammal an effective amount of a agent for a time and under conditions sufficient to antagonize the interaction between a *P. gingivalis*-derived molecule having an HA2 domain and an HA2-binding motif on hemoglobin.

11. A method for the prophylaxis or treatment of *P. gingivalis* infection or infection by a related microorganism in a mammal, said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to antagonize the interaction between a *P. gingivalis*-derived HA2- containing molecule comprising the amino acid sequence ALNPPNYLISKDVTG <400>1 or ALNPDNYLISKDVTGATKVKY <400>8 or an amino acid sequence having at least 40% similarity to <400>1 or <400>8 or at least about 20% identity after optimum alignment with same sequence or an amino acid sequence encoded by the nucleotide sequence <400>7 or a nucleotide sequence having at least 40% similarity thereto or a nucleotide sequence capable of hybridizing thereto under low stringency conditions and an HA2-binding motif comprising and including propionic acid groups or anionic or salt forms thereof such as but not limited to the region defined by substructure (Ic) in Formula (I) on a porphyrin-containing molecule such as but not limited to hemoglobin or a precursor form thereof or part thereof such as heme.

12. An agent capable of antagonizing interaction between an HA2-containing molecule and an HA2-binding motif on a porphyrin-containing molecule such as but not limited

- 59 -

to hemoglobin or a precursor form thereof or part thereof such as heme.

13. An agent according to Claim 12 wherein the porphyrin is heme.

14. An agent according to Claim 12 or 13 wherein said agent comprises propionic groups in planar alignment with respect to the molecular structure of said agent.

15. Use of a gingipain or an HA2 domain containing part thereof or an HA2-containing molecule in the manufacture of a medicament for the prevention or treatment of *P. gingivalis* infection or infection by a related microorganism.

16. Use of an antagonist of *P. gingivalis*-derived HA2-containing molecule interaction with a porphyrin-containing molecule such as but not limited to hemoglobin or a precursor form thereof or part thereof such as heme in the manufacture of a medicament for the prophylaxis or treatment of *P. gingivalis* infection or infection by a related microorganism.

17. A therapeutic composition comprising an agent according to any one of Claims 12 to 14 and one or more pharmaceutically acceptable carriers and/or diluents.